Shuttle Pharmaceuticals News

Shuttle Pharmaceuticals | 8-K: Current report

Apr 29 10:08 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024

Apr 23 16:42 ET

Shuttle Pharmaceuticals | S-1: General form for registration of securities under the Securities Act of 1933

Apr 5 17:10 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Fourth Quarter 2023 Corporate Update

Mar 22 09:02 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmicals Receives Notice of Nasdaq's Failure to Satisfy Continued Listing Rules and CEO Anatoly Dritschilo to Attend Emerging Growth Conference on March 6, 2024

Mar 5 09:02 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Feb 13 08:04 ET

Shuttle Pharmaceuticals | 8-K: Asset Purchase Agreement

Feb 5 16:28 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Jan 8 00:00 ET

Shuttle Pharmaceuticals | 8-K: Poll Results of 2023 Stockholders Meeting

Dec 19, 2023 17:10 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Dec 11, 2023 09:00 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023

Nov 30, 2023 09:00 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Nov 14, 2023 09:12 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement

Oct 30, 2023 17:14 ET

Shuttle Pharmaceuticals | DEF 14A: Definitive information statements

Oct 20, 2023 16:10 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 10, 2023 09:00 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Enters into Consulting Agreement with Joseph D. Armstrong, Iii, Ph.D.

Oct 5, 2023 16:10 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Sep 25, 2023 09:00 ET

Shuttle Pharmaceuticals | 8-K: Current report

Sep 7, 2023 09:20 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update

Aug 15, 2023 09:00 ET

Shuttle Pharmaceuticals | 8-K: Shuttle Pharmaceuticals Completes Manufacturing of Active Pharmaceutical Ingredient (API) for Use in Clinical Trial

Aug 3, 2023 09:00 ET